BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15963292)

  • 1. Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999-2003.
    Malhotra-Kumar S; Lammens C; Chapelle S; Wijdooghe M; Piessens J; Van Herck K; Goossens H
    Emerg Infect Dis; 2005 Jun; 11(6):939-42. PubMed ID: 15963292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.
    Mazzariol A; Koncan R; Bahar G; Cornaglia G
    J Chemother; 2007 Oct; 19(5):500-7. PubMed ID: 18073148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Declining macrolide resistance in Streptococcus pyogenes in Portugal (2007-13) was accompanied by continuous clonal changes.
    Silva-Costa C; Ramirez M; Melo-Cristino J;
    J Antimicrob Chemother; 2015 Oct; 70(10):2729-33. PubMed ID: 26142474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations.
    Farrell DJ; Shackcloth J; Barbadora KA; Green MD
    Antimicrob Agents Chemother; 2006 Feb; 50(2):817-8. PubMed ID: 16436755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004.
    Tamayo J; Pérez-Trallero E; Gómez-Garcés JL; Alós JI;
    J Antimicrob Chemother; 2005 Oct; 56(4):780-2. PubMed ID: 16120627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003.
    Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Miller AL; Rice CL; Doern CD; Reid SD; Doern GV
    Clin Infect Dis; 2005 Sep; 41(5):599-608. PubMed ID: 16080080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrolide-resistant genes of Streptococcus pyogenes isolated from the upper respiratory tract by polymerase chain reaction.
    Billal DS; Hotomi M; Yamauchi K; Fujihara K; Tamura S; Kuki K; Sugita R; Endou M; Mukaigawa J; Yamanaka N
    J Infect Chemother; 2004 Apr; 10(2):115-20. PubMed ID: 15160306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United States.
    Green M; Allen C; Bradley J; Dashefsky B; Gilsdorf JR; Marcon MJ; Schutze GE; Smith C; Walter E; Martin JM; Edwards KA; Barbadora KA; Rumbaugh RM; Wald ER
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2487-9. PubMed ID: 15917551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of macrolide-resistant Streptococcus pyogenes strains in French children.
    Bingen E; Bidet P; Mihaila-Amrouche L; Doit C; Forcet S; Brahimi N; Bouvet A; Cohen R
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3559-62. PubMed ID: 15328126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What causes decreased erythromycin resistance in Streptococcus pyogenes? Dynamics of four clones in a southern European region from 2005 to 2012.
    Montes M; Tamayo E; Mojica C; García-Arenzana JM; Esnal O; Pérez-Trallero E
    J Antimicrob Chemother; 2014 Jun; 69(6):1474-82. PubMed ID: 24562616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.
    Norrby SR; Quinn J; Rangaraju M; Leroy B
    Clin Microbiol Infect; 2004 Jul; 10(7):615-23. PubMed ID: 15214873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of macrolide and tetracycline resistance mechanisms in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin.
    Betriu C; Culebras E; Redondo M; Rodríguez-Avial I; Gómez M; Boloix A; Picazo JJ
    J Antimicrob Chemother; 2002 Sep; 50(3):436-8. PubMed ID: 12205076
    [No Abstract]   [Full Text] [Related]  

  • 14. Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin.
    Morosini MI; Cantón R; Loza E; del Campo R; Almaraz F; Baquero F
    J Antimicrob Chemother; 2003 Jul; 52(1):50-5. PubMed ID: 12805254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mef(A) is the predominant macrolide resistance determinant in Streptococcus pneumoniae and Streptococcus pyogenes in Germany.
    Bley C; van der Linden M; Reinert RR
    Int J Antimicrob Agents; 2011 May; 37(5):425-31. PubMed ID: 21419605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analysis of Streptococcus pyogenes macrolide resistance of paediatric isolates during a 7 year period (2007-13).
    Michos A; Koutouzi FI; Tsakris A; Chatzichristou P; Koutouzis EI; Daikos GL; Stathi A; Syriopoulou VP
    J Antimicrob Chemother; 2016 Aug; 71(8):2113-7. PubMed ID: 27118782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and characterization of macrolide resistance in clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes from North America.
    Hoban DJ
    J Chemother; 2002 Jul; 14 Suppl 3():25-30. PubMed ID: 12418558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid increase in macrolide resistance in Streptococcus pyogenes isolated in Poland during 1996-2002.
    Szczypa K; Sadowy E; Izdebski R; Hryniewicz W
    J Antimicrob Chemother; 2004 Oct; 54(4):828-31. PubMed ID: 15329367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromcycin versus comparators.
    Shackcloth J; Williams L; Farrell DJ
    J Infect; 2004 Apr; 48(3):229-35. PubMed ID: 15001301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of antimicrobial susceptibility of clinical isolates of Streptococcus pyogenes in Japan: report of a countrywide surveillance study.
    Hotomi M; Billal DS; Shimada J; Yamauchi K; Fujihara K; Yamanaka N;
    J Infect Chemother; 2005 Feb; 11(1):48-51. PubMed ID: 15729489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.